{"We": [0], "report": [1], "the": [2], "first": [3], "5-year": [4], "follow-up": [5], "of": [6, 28, 49], "any": [7], "first-line": [8], "phase": [9], "III": [10], "immunotherapy": [11], "trial": [12, 27], "for": [13], "non-small-cell": [14], "lung": [15], "cancer": [16], "(NSCLC).": [17], "KEYNOTE-024": [18], "(ClinicalTrials.gov": [19], "identifier:": [20], "NCT02142738)": [21], "is": [22], "an": [23], "open-label,": [24], "randomized": [25], "controlled": [26], "pembrolizumab": [29], "compared": [30], "with": [31, 36, 40], "platinum-based": [32], "chemotherapy": [33], "in": [34], "patients": [35], "previously": [37], "untreated": [38], "NSCLC": [39], "a": [41], "programmed": [42], "death": [43], "ligand-1": [44], "(PD-L1)": [45], "tumor": [46], "proportion": [47], "score": [48], "at": [50], "least": [51], "50%": [52], "and": [53], "no": [54], "sensitizing": [55]}